Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record.

Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging study

Open access
Jacobi, Annett M., Huang, Weiqing, Wang, Tao, Freimuth, William, Sanz, Inaki, Furie, Richard, Mackay, Meggan, Aranow, Cynthia, Diamond, Betty, Davidson, Anne·2010·Arthritis & Rheumatism

Abstract

Objective: To understand the effects of long‐term BLyS inhibition in human systemic lupus erythematosus (SLE). Methods: Seventeen patients with SLE who were enrolled in a clinical trial of belimumab, a BLyS‐specific inhibitor, plus standard of care therapy were studied. Phenotypic analysis of lymphocytes was performed using flow cytometry. Circulating antibody‐secreting cells were enumerated using enzyme‐linked immunospot assay. Serum was analyzed by enzyme‐linked immunosorbent assay using an antibody that recognizes products of the V H 4–34 gene. Lymphocyte counts, Ig levels, and anti–double‐stranded DNA antibody levels were available as part of the clinical trial analyses. Results: Samples were collected on days 0, 84, 168, 365, and 532 and after day 730. The total number of B cells started to decrease from baseline between days 84 and 168. This was due to a decrease in naive and transitional B cells. CD27+IgD+ memory B cells and plasmablasts decreased only after 532 days, whereas CD27+IgD− memory B cells were not affected, and there were no changes in T cells. Serum IgM levels began to decline between days 84 and 168, but there were no changes in serum levels of IgG, IgG anti‐DNA antibodies, or V H 4–34 antibodies during the study. SLE patients had more IgM‐, IgG‐, and autoantibody‐producing B cells than did normal controls on day 0. There was only a modest decrease in the frequency of total IgM‐producing, but not IgG‐producing, cells on days 365 and 532, consistent with the phenotypic and serologic data. Conclusion: Our data confirm the dependence of newly formed B cells on BLyS for survival in humans. In contrast, memory B cells and plasma cells are less susceptible to selective BLyS inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.27189

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 243

Metadata

Authors
Jacobi, A. M., Huang, W., Wang, T., Freimuth, W., Sanz, I., Furie, R., Mackay, M., Aranow, C., Diamond, B., & Davidson, A.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2009-12-28
Volume
62
Issue
1
Pages
201-210
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2078800870
Cited by
243
References
0
FWCI
16.06
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging study. https://app.cochat.ai/papers/10.1002/art.27189
The paper
Jacobi, A. M., Huang, W., Wang, T., Freimuth, W., Sanz, I., Furie, R., Mackay, M., Aranow, C., Diamond, B., & Davidson, A. (2010). Effect of long‐term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double‐blind, placebo‐controlled, dose‐ranging study. Arthritis & Rheumatism. https://doi.org/10.1002/art.27189

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.